Stereotactic Radiation for Palliation of Skull Base Recurrences of Salivary Gland Carcinomas: Implications for Tumor Targeting

Abstract

Background Approximately 3 to 13% of salivary carcinomas recur at the skull base. We report our experience treating these recurrences with stereotactic radiation.

Methods In total, 14 patients with skull base recurrence of salivary gland carcinoma were identified. Patient characteristics, treatment parameters, response to treatment, local recurrence-free/overall survival, and patterns of failure were studied.

Results All 12 symptomatic patients experienced palliation of symptoms. Two grade 3 toxicities were observed. Local recurrence-free survival after skull base treatment was 28 months (74 months after allowing for additional course of salvage radiotherapy). Overall survival was 153 months from primary diagnosis and 67 months from first skull base failure. Of 13 treatment failures, 8 occurred at margins; the rest were infield. All intracranial failures occurred along meningeal surfaces.

Conclusions Stereotactic radiation provides well-tolerated palliation for the majority of patients, but with a high rate of local failure. Due to the propensity for meningeal failures, we suggest increasing margins along the meningeal surfaces when treating these patients.

Keywords

salivary gland carcinoma - skull base recurrence - stereotactic radiation - palliation - radiosurgery

Note

Presented at the 35th annual North American Skull Base Society Meeting.

• References

• 1 Terhaard CHJ, Lubsen H, Van der Tweel I , et al; Dutch Head and Neck Oncology Cooperative Group. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004; 26 (8) 681-692 , discussion 692–693
• 2 Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW. Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 2007; 67 (4) 982-987
• 3 Terhaard CHJ, Lubsen H, Rasch CRN , et al; Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005; 61 (1) 103-111
• 4 Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995; 32 (3) 619-626
• 5 Chen AM, Garcia J, Granchi P, Bucci MK, Lee NY. Base of skull recurrences after treatment of salivary gland cancer with perineural invasion reduced by postoperative radiotherapy. Clin Otolaryngol 2009; 34 (6) 539-545
• 6 Kim J, Lee J, Wu H , et al. Impact of radiation therapy volumes on skull base recurrence in adenoid cystic carcinoma in the head and neck. Int J Radiat Oncol 2014; 90 (1) S545-S546
• 7 Tishler RB, Loeffler JS, Lunsford LD , et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys 1993; 27 (2) 215-221
• 8 Lee N, Millender LE, Larson DA , et al. Gamma knife radiosurgery for recurrent salivary gland malignancies involving the base of skull. Head Neck 2003; 25 (3) 210-216
• 9 Mori Y, Kobayashi T, Kida Y, Oda K, Shibamoto Y, Yoshida J. Stereotactic radiosurgery as a salvage treatment for recurrent skull base adenoid cystic carcinoma. Stereotact Funct Neurosurg 2005; 83 (5–6): 202-207
• 10 Zhang C-Y, Mao L, Li L , et al. Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer 2007; 110 (1) 87-95